Effect of Huanglian Wendan decoction on chronic atrophic gastritis patients with anxiety and depression

doi:10.3877/cma.j.issn.2095-2015.2024.02.011

Abstract

Abstract:

Objective

To explore the therapeutic effect of Huanglian Wendan decoction on chronic atrophic gastritis (CAG) patients with anxiety and depression, and its impact on traditional Chinese medicine syndrome score and anxiety and depression scale score.

Methods

A total of 104 CAG patients with anxiety and depression admitted to Fuyang Cancer Hospital in Anhui Province from January 2019 to January 2022 were selected and randomly divided into the observation group (52 cases treated with conventional Western medicine) and the control group (52 cases treated with Huanglian Wendan decoction on the basis of Western medicine). The clinical efficacy, traditional Chinese medicine syndrome score, anxiety and depression score and gastric mucosa function related indexes were compared between the two groups.

Results

After treatment, the clinical treatment effectiveness rate of the observation group was significantly higher than that of the control group (P<0.05), and the traditional Chinese medicine syndrome scores such as epigastric distension and pain in the observation group were significantly lower than those of the control group (P<0.05). The anxiety scale (Hamilton Anxiety Scale, HAMA) and depression scale (Hamilton Depression Scale, HAMD) scores of the observation group were lower than those of the control group (P<0.05), and the pepsinogen (PG) Ⅰ and PGⅠ/PGⅡ ratio of the observation group were higher than those of the control group (P<0.05). There was no significant difference in PGⅡ between the observation group and the control group (P>0.05).

Conclusion

Huanglian Wendan decoction is effective in the treatment of CAG patients with anxiety and depression, and can effectively improve the clinical symptoms, anxiety and depression and gastric mucosa function.

Key words: Chronic atrophic gastritis, Huanglian Wendan decoction, Anxiety, Depression, Scoring of Traditional Chinese medicine syndrome score

Yafei Wang, Ting Deng, Jiangtao Xu, Dandan Geng, Xiaomei Wang. Effect of Huanglian Wendan decoction on chronic atrophic gastritis patients with anxiety and depression[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(02): 155-158.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2024.02.011

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2024/V14/I02/155

Figures/Tables 4

References 14

[1]	Botezatu A, Bodrug N. Chronic atrophic gastritis: an update on diagnosis[J]. Med Pharm Rep, 2021, 94(1): 7-14.
[2]	王强, 杨光, 王健, 等. 多塞平联合四联疗法对HP相关慢性胃炎合并抑郁患者的临床疗效观察[J]. 国际精神病学杂志, 2021, 48(3): 496-499.
[3]	贺新国, 郭保根. 黄连温胆汤联合铋剂四联疗法治疗脾胃湿热证H. pylori相关慢性胃炎的疗效及对胃黏膜TGF-β1、Smad3表达的影响[J]. 四川中医, 2021, 39(9): 93-96.
[4]	桑贤港, 韩宇博, 邹国良, 等. 黄连温胆汤加减对冠心病伴焦虑、抑郁状态患者治疗效果及血清炎症反应及脑源性神经营养因子、核转录因子-κB、5-羟色胺、P物质水平的影响[J]. 世界中西医结合杂志, 2022, 17(3): 566-570.
[5]	Shah SC, Piazuelo MB, Kuipers EJ, et al. AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review[J]. Gastroenterology, 2021, 161(4): 1325-1332.
[6]	中华医学会精神病学分会. 中国精神障碍分类与诊断标准[M]. 3版. 济南: 山东科技出版社, 2001: 87-89.
[7]	中华医学会消化病学分会. 中国慢性胃炎共识意见(2017年,上海)[J]. 胃肠病学, 2017, 22(11): 670-687.
[8]	中华中医药学会脾胃病分会. 慢性萎缩性胃炎中医诊疗共识意见[J]. 中医杂志, 2010, 51(8): 749-753.
[9]	华自森, 余军, 刘俊. 柴胡舒肝散加减治疗肝胃不和型慢性非萎缩性胃炎合并焦虑、抑郁患者的临床疗效观察[J]. 四川中医, 2021, 39(4): 106-110.
[10]	Wu H, Liang G, Kong M, et al. The status and risk factors for anxiety/depression in patients with atrophic chronic gastritis: a cross-sectional study[J]. Ann Palliat Med, 2022, 11(10): 3147-3159.
[11]	汪湃, 冯世兵, 刘宏伟, 等. 温针灸联合黄连温胆汤治疗慢性浅表性胃炎的疗效[J]. 世界中医药, 2020, 15(14): 2155-2158, 2162.
[12]	干晓花, 袁成业. 健脾清热化湿汤对脾胃湿热型慢性萎缩性胃炎患者中医症候积分,萎缩评分及PGI, PGII的影响[J]. 四川中医, 2021, 39(12): 109-112.
[13]	贾庆玲, 王煜姣, 丛军, 等. 基于网络药理学探讨莪术—黄连药对治疗慢性萎缩性胃炎的作用机制[J]. 山东医药, 2022, 62(2): 18-21.
[14]	范志欣, 杨晓军, 黄敏玲, 等. 基于网络药理学探讨黄连温胆汤"心胃同治"作用机制[J]. 现代中西医结合杂志, 2020, 29(25): 2788-2792, 2810.

组别	例数	年龄(岁,±s)	性别[例(%)]		病程(月,±s)	萎缩程度[例(%)]
组别	例数	年龄(岁,±s)	男	女	病程(月,±s)	轻	中	重
观察组	52	53.39±8.28	22(42.31)	30(57.69)	7.45±1.23	22(42.31)	25(48.08)	5(9.61)
对照组	52	54.45±8.07	24(46.15)	28(53.85)	7.78±1.51	20(38.46)	27(51.92)	5(93.61)
χ²/t值		0.859	0.849		0.854	0.762
P值		0.485	0.359		0.387	0.324

组别	例数	年龄(岁,±s)	性别[例(%)]		病程(月,±s)	萎缩程度[例(%)]
组别	例数	年龄(岁,±s)	男	女	病程(月,±s)	轻	中	重
观察组	52	53.39±8.28	22(42.31)	30(57.69)	7.45±1.23	22(42.31)	25(48.08)	5(9.61)
对照组	52	54.45±8.07	24(46.15)	28(53.85)	7.78±1.51	20(38.46)	27(51.92)	5(93.61)
χ²/t值		0.859	0.849		0.854	0.762
P值		0.485	0.359		0.387	0.324

组别	例数	时间	胃脘胀痛	痞满烦闷	食少纳呆	嘈杂反酸
观察组	52	治疗前	2.43±0.31	2.36±0.39	2.25±0.29	2.37±0.27
观察组	52	治疗后	1.23±0.21^ac	1.28±0.24^ac	1.16±0.30^ac	0.95±0.18^ac
对照组	52	治疗前	2.48±0.29	2.31±0.36	2.36±0.32	2.38±0.29
对照组	52	治疗后	1.45±0.23^b	1.39±0.19^b	1.36±0.21^b	1.28±0.20^b
t值			4.592/3.562/5.590	3.699/3.021/5.062	4.032/3.264/4.695	4.064/3.621/4.852
P值^a/b/c			0.007/0.020/0.000	0.018/0.026/0.002	0.010/0.024/0.008	0.009/0.020/0.005

组别	例数	时间	胃脘胀痛	痞满烦闷	食少纳呆	嘈杂反酸
观察组	52	治疗前	2.43±0.31	2.36±0.39	2.25±0.29	2.37±0.27
观察组	52	治疗后	1.23±0.21^ac	1.28±0.24^ac	1.16±0.30^ac	0.95±0.18^ac
对照组	52	治疗前	2.48±0.29	2.31±0.36	2.36±0.32	2.38±0.29
对照组	52	治疗后	1.45±0.23^b	1.39±0.19^b	1.36±0.21^b	1.28±0.20^b
t值			4.592/3.562/5.590	3.699/3.021/5.062	4.032/3.264/4.695	4.064/3.621/4.852
P值^a/b/c			0.007/0.020/0.000	0.018/0.026/0.002	0.010/0.024/0.008	0.009/0.020/0.005

组别	例数	时间	HAMA评分	HAMD评分
观察组	52	治疗前	16.26±3.59	15.37±3.20
观察组	52	治疗后	7.56±1.65^ac	6.38±1.04^ac
对照组	52	治疗前	16.37±3.41	15.67±3.89
对照组	52	治疗后	11.03±2.31^b	11.52±2.32^b
t值			5.564/4.231/6.032	6.264/5.237/6.452
P值^a/b/c			0.003/0.008/0.000	0.000/0.004/0.000

Please choose a citation manager

Content to export